H3 Pharma Plans First Quarter Response To Sanvar IR "Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA letter requests additional supportive efficacy data and further information related to manufacturing. H3 Pharma expects that the results from a recently completed Phase III study will address the issues cited in the letter.
You may also be interested in...
Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA
A Special Protocol Assessment is no guarantee of FDA approval, or even a smooth development path
Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA
A Special Protocol Assessment is no guarantee of FDA approval, or even a smooth development path
Debiopharm Takes Up Confirmatory Phase III Trial Of Sanvar
The esophageal variceal bleeding treatment received an FDA “approvable” letter in 2004.